Atea Pharmaceuticals, Inc. AVIR 深 滬
等待開盤 09-17 09:30:00 美东时间
5.15
-0.080
-1.53%
華盛通- 最 高5.33
- 今 開5.23
- 成交量 27.42万股
- 最 低 5.15
- 昨 收 5.23
- 總市值 4.13亿
- 52周最高 6.45
- 市盈率 靜 --
- 換手率 0.34%
- 52周最低 2.78
- 委 比 42.36%
- 總股本 8020.47万
- 歷史最高 94.174
- 量 比 0.82
- 振 幅 3.44%
- 歷史最低 2.455
- 每 手 1
- 風險率 1.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Atea Pharmaceuticals announced that its CEO and management team will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The presentation will discuss the company's oral antiviral therapies for serious viral diseases, including its Phase 3 program for hepatitis C and Phase 1 program for hepatitis E. A live webcast will be available online, with an archive accessible for 90 days post-event. The company emp...
09-08 11:00
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
08-13 22:15
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals reported positive results from its Phase 3 C-BEYOND trial for BEM/RZR in treating chronic hepatitis C virus (HCV), achieving primary and secondary endpoints with an 8-week regimen for non-cirrhotic patients. The company also announced progress in its C-FORWARD trial outside North America and initiated a Phase 1 trial for AT-587 targeting hepatitis E virus (HEV). Financially, Atea reported $219.5 million in cash and investment...
08-12 20:05
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
Atea Pharmaceuticals will host a live conference call and audio webcast on August 12, 2026, at 4:30 p.m. ET to discuss Q2 2026 financial results and provide a business update. Participants can register via the provided link or dial 1-877-407-0779 (U.S.) or 1-201-389-0914 (International) using conference ID 13761501. An audio webcast archive will be available on Atea’s website two hours post-call and remain accessible for 90 days. The company focu...
08-05 11:00
Atea Pharmaceuticals Says Topline Data From C-BEYOND Phase 3 Trial Of Once-daily Fixed-Dose Combination Of Bemnifosbuvir and Ruzasvir for Chronic Hepatitis C Virus Infection Shows Statistical Non-Inferiority Vs. Fixed-Dose Combination Of Sofosbuvir and Velpatasvir
In the mITT analysis (n=905, cirrhotic and non-cirrhotic), BEM/RZR achieved a 93.9% sustained virologic response (SVR) rate vs. 94.8% for SOF/VEL (Epclusa) at Week 24, encompassing SVR at 12 weeks post-treatment (accepted definition of cure for HCV) in both arms. These results achieved the primary e...
07-28 19:09
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Atea Pharmaceuticals' BEM/RZR achieved statistical non-inferiority to SOF/VEL in treating chronic HCV, with 93.9% SVR in the mITT population. BEM/RZR's 8-week regimen for non-cirrhotic patients showed high cure rates, potentially streamlining treatment and improving patient outcomes. The study highlights BEM/RZR's potential as a best-in-class therapy with fewer drug interactions and flexibility in administration.
07-28 11:00
Atea Pharmaceuticals Initiates First-in-human Phase 1 Clinical Trial Of AT-587 For Hepatitis E Virus Infection
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587,...
07-14 19:05
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Atea Pharmaceuticals has initiated a Phase 1 clinical trial for AT-587, a potential first-in-class oral antiviral treatment for hepatitis E virus (HEV), a serious liver disease with no approved therapies. The trial aims to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. AT-587 shows high antiviral potency against HEV in preclinical studies and may address a significant unmet need for immunocompromised patients. The stud...
07-14 11:00
Atea Pharma Completes Patient Enrollment In C-FORWARD, Phase 3 Clinical Trial Outside North America, Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus Infection
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for the Treatment of HCV BOSTON...
06-25 19:08
